Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease

• Published in: Anticancer research Vol. 41; no. 11; pp. 5635 - 5642
• Main Authors: SAITO, TAKASHI, OHNISHI, KAYOKO, ISHIKAWA, HITOSHI, NAKAMURA, MASATOSHI, HOSHIAI, SODAI, NUMAJIRI, HARUKO, MUROFUSHI, KEIKO NEMOTO, MIZUMOTO, MASASHI, OKUMURA, TOSHIYUKI, SAKURAI, HIDEYUKI
• Format: Journal Article
• Language: English
• Published: Athens International Institute of Anticancer Research 01.11.2021
• Subjects: Lung cancer; Lung diseases; Non-small cell lung carcinoma; Patients; Pneumonitis; Proton beams; Small cell lung carcinoma
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15379

Background/Aim: To evaluate the outcomes of proton beam therapy (PBT) for early-stage non-small cell lung cancer (NSCLC) in patients with interstitial lung disease (ILD). Patients and Methods: Between 2002 and 2017, 110 patients receiving hypofractionated PBT for cT1-2N0M0 NSCLC were reviewed. Results: Of the 110 patients, 17 were diagnosed with ILD. The median follow-up period was 37.8 months. No significant difference in the 1-year cumulative rate of grade ≥2 pneumonitis was observed between patients with and those without ILD (17.6% vs. 14.1%, p=0.708). The lung doses were significantly lower in patients with than in those without ILD among patients without grade ≥2 pneumonitis. There were no significant differences in overall survival or local recurrence-free rates according to the presence of ILD. Conclusion: PBT appears to be a feasible and effective treatment for cT1-2N0M0 NSCLC in patients with ILD, but the lung dose should be strictly reduced.